MD, PhD, eMBA, Founder & CEO and Chairman of the Board
Akseli Hemminki is the founder, CEO and Board Chairman of TILT Biotherapeutics, and Professor of Oncology at the University of Helsinki. In addition to his world leading medical and scientific track record with oncolytic viruses, Akseli has solid experience with founding, financing, and operation of biotech firms. Akseli founded TILT in 2013, rapidly securing multiple rounds of seed financing.
Prior to founding TILT, he had co-founded Oncos Therapeutics Ltd (currently Targovax ASA), a company involved in the clinical development of oncolytic viruses. Akseli served as Chairman of the Board, Chief Scientific Officer, and Board member at Oncos. He also pioneered individualized patient-by-patient use of oncolytic immunotherapy under the EU Advanced Therapy Directive, and personally treated around 300 patients using 10 different oncolytic adenoviruses. He continues to see cancer patients giving him hands-on knowledge in clinical application of immuno-oncology.
Akseli has authored nearly 300 peer-reviewed manuscripts or book chapters on cancer research and oncolytic viruses, many of them published in the best journals of the field. He has been involved in a dozen clinical trials in Europe and U.S. He is also an inventor on >10 patent applications relating to oncolytic viruses, including all of TILT´s patents.
MSc, MS, Chief Business Officer
MD, PhD, MBA, Chief Medical Officer
MSc, Head of CMC Regulatory Affairs
PhD, Head of Clinical Operations
PhD, Head of Clinical Research
M.Pharm, Head of Immunology
PhD, Head of R&D
Bachelor of Social and Health Care, Lab manager
MSc, Head of Cell Therapy
PhD, CMC Advisor
PhD, Chief Regulatory Officer
MSc (Tech), Strategy Advisor, Member of the Board of Directors
Legal Advisor, Member of the Board of Directors
MSc, Member of the Board of Directors
MSc (Pharm), Strategy/Commercial Advisor, Member of the Board of Directors
MSc, Business and Administration, Senior Business Advisor